ABOUT

Cambium Plant Sciences is leading the agricultural revolution of cannabis genetics, redefining consumer experiences and cultivation economics across the global cannabis industry. With the systematic application of research, technology and science, Cambium is developing the next generation of premium cannabis genetics for recreational, medical and wellness applications. Cambium’s innovative mission is to supply agriculturally-focused, disease resistant, premium seed stock to the rapidly growing global cannabis market.

The Cannabis industry has not yet had the benefit of the agricultural revolution that transformed commercial agriculture on a global scale over the past century. Cambium will play a leading role in revolutionizing strain development to enhance cultivation economics across the globe. Located in a state-of-the-art, 34,000 sqft research and development facility in Goderich, Ontario, Cambium is developing cultivars that benefit domestic and global cultivation and manufacturing partners.

By revolutionizing strain development and enhancing broader industry outputs, Cambium will lead the cannabis industry with our proprietary genetics and cultivation techniques.

Cambium will use proprietary research, technology and scientific methodologies to revolutionize recreational, medical and wellness cannabis cultivation.

From the next blockbuster recreational strain to disease resistant agricultural seed stock, Cambium will improve cannabis production and its economics by pushing the boundaries of the plant.

LEADERSHIP

Alan Darlington, PhD
General Manager

Matt Rogge
Director of Genetic Development